Open Orphan to become '$1bln firm in very near future' after COVID-19 study receives ethics approval

Open Orphan PLC's (LON:ORPH) Cathal Friel talks to Proactive London's Katie Pilbeam about the world’s first COVID-19 characterisation study receiving approval from a specially convened Research Ethics Committee (REC). 

This follows a contract received by the company’s subsidiary hVIVO from the UK government to develop a COVID-19 human challenge study model.

Friel explains that the vaccines industry has been the 'cinderella' of the sector for so many years, but is now growing fast.